* InspireMD Inc NSPR.OQ NSPR.O is expected to show a
rise in
quarterly revenue when it reports results on May 14 for the
period ending March 31 2024
* The Tel Aviv-yafo Israel-based company is expected to
report a
11.7% increase in revenue to $1.384 million from $1.24 million a
year ago, according to the estimate from one analyst, based on
LSEG data.
* LSEG's mean analyst estimate for InspireMD Inc is for a
loss
of 15 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for InspireMD
Inc is
$4.50, above its last closing price of $2.21.
This summary was machine generated May 10 at 12:45 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)